MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...

A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, researchers said.

Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer The 21-gene recurrence score (RS) breast cancer assay is clinically used to ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

A risk score based on four factors — male sex, tumor size, World Health Organization (WHO) grade, and lymphovascular invasion — predicts recurrence in patients with node-negative pancreatic ...